NYSE$NGVT

Ingevity Corporation · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Reported a net loss due to restructuring charges and contract termination fees, but saw strength in Performance Materials and Advanced Polymer Technologies.

Ingevity reported a 16% decrease in net sales to $376.9 million, primarily due to repositioning actions in Performance Chemicals. The company experienced a net loss of $107.2 million, which includes significant restructuring charges and contract termination fees. However, adjusted earnings were $40.2 million, with an adjusted EPS of $1.10. The company affirms its full-year guidance for sales and adjusted EBITDA.

  • Net sales decreased by 16% year-over-year to $376.9 million.
  • Net loss was $107.2 million, impacted by restructuring and contract termination costs.
  • Adjusted EBITDA was $106.4 million with a margin of 28.2%.
  • Full year guidance affirmed with sales expected between $1.40 billion and $1.50 billion, and adjusted EBITDA between $350 million and $360 million.

Headline financials

Total Revenue

$377M

Previous: $446M-15.5%
EPS (adj)

$1.10

Previous: $1.21-9.1%
Capital Expenditures

-$18M

Previous: -$33.5M+46.3%
Free Cash Flow

-$107M

Previous: $25.2M-525.4%
Net Income

-$107M

Previous: $25.2M-525.4%
Operating Income

$110M

Previous: $110M-0.2%
Gross Profit

$130M

Previous: $129M+0.7%
Cash & Equivalents

$136M

Previous: $84.5M+60.4%
Total Assets

$2.21B

Previous: $2.77B-20.1%
R&D Expense

$6.7M

Previous: $7.8M-14.1%

Revenue & EPS history

Ingevity · Revenue · Quarterly

$377M

Q3 2024-15.5%vs Q3 2023
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Revenue by segment

Ingevity · $446M total across 3 segments · Q3 2023

  • Performance Chemicals
    $256M-24.1%
  • Performance Materials
    $147M+1.6%
  • Advanced Polymer Tech
    $42.8M

Forward guidance

Ingevity is affirming its full year 2024 guidance of sales between $1.40 billion and $1.50 billion and adjusted EBITDA between $350 million and $360 million.

Tailwinds

  • Positive impact from Performance Chemicals segment repositioning.
  • Focus on maximizing benefits of strategy through execution.
  • Sales between $1.40 billion and $1.50 billion.
  • Adjusted EBITDA between $350 million and $360 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

+1.9%

Avg return

Earnings day

+1.9%

Avg return

5 days after

+2.2%

Avg return

30 days after

58%

26 / 45 earnings

Positive

+22.0%

Q1 2020

Best reaction

-15.8%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.9%-8.2%-15.3%
Q4 2025+0.3%+1.5%+1.4%
Q3 2025-15.8%-9.1%-2.8%
Q1 2025+0.9%+9.8%+7.3%
Q4 2024+5.3%+0.6%-7.5%
Q3 2024+16.5%+17.5%+33.5%
Q2 2024-7.5%-23.2%-14.3%
Q1 2024+7.2%+5.3%-4.5%
Q4 2023+3.1%+4.7%+3.1%
Q3 2023+5.0%-0.5%+1.1%
Q2 2023-11.2%-14.0%-12.4%
Q1 2023-8.4%-15.9%-26.3%
Q4 2022-6.8%-7.8%-21.1%
Q3 2022+3.6%+8.2%+14.1%
Q2 2022+5.0%+3.0%+4.2%
Q1 2022+9.6%+9.2%+19.7%
Q4 2021+0.9%+4.2%-0.5%
Q3 2021-0.6%-0.5%-5.6%
Q2 2021+5.4%+1.4%-1.0%
Q1 2021+4.6%+10.2%+10.4%
Q4 2020-6.6%-4.6%+6.3%
Q3 2020-1.4%+0.1%+8.9%
Q2 2020-2.1%+1.9%+1.3%
Q1 2020+22.0%+12.2%+23.8%
Q4 2019-2.9%+2.5%-24.5%
Q3 2019+1.7%+2.8%+4.6%
Q2 2019-1.2%-2.9%-26.9%
Q1 2019-10.9%-9.8%-23.7%
Q4 2018+9.8%+13.2%+3.0%
Q3 2018+2.3%-0.6%+9.8%
Q2 2018+11.3%+10.0%+14.5%
Q1 2018+2.4%+2.7%-0.2%
Q4 2017+7.3%+12.3%+3.8%
Q3 2017+2.2%+5.8%+11.0%
Q2 2017-0.7%+1.3%+8.1%
Q1 2017-6.5%-7.2%-5.4%
Q4 2014+4.3%+2.5%+6.7%
Q4 2016-4.6%-6.8%+7.0%
Q3 2015+11.0%+10.8%+22.7%
Q3 2016+7.2%+8.3%+21.1%
Q2 2015+14.3%+14.8%+17.2%
Q2 2016+15.8%+15.8%+18.4%
Q1 2016-0.3%
Q1 2015-0.3%
Q4 2015-0.3%
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro